| | Hey traders! It's Michael here with the Stock Dork Cheat Sheet: Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks! Happy Friday! It's November 3rd. I hope you have a great weekend. Now, let's get ready to trade! |
Stocks gained again on Thursday, as investors cheered the Fed's decision to hold rates steady. The S&P 500 led the way with a 1.8% rally, followed closely behind by the Dow & Nasdaq, who both gained 1.7%. However, the real star of the show was the small-cap Russell 2K with a 2.6% rally. This morning, futures are in a holding pattern ahead of today's jobs report. S&P 500 contracts are holding near flat. An Overlooked Industry Seeing 2,162% Gains The U.S. government is moving towards electric cars, and European countries are phasing out gas-powered vehicles entirely, with Norway banning oil and gas and England following by 2030. This proves the future is in electricity. Investors are flocking to get in before this company gets a deal like Mercedes gave to their partner. Get the Details Here Before it Takes Off 🍎 Something's Rotten at Apple Shares of Apple [AAPL] are trending down after the company released its latest quarterly results following Thursday's close. Apple reported stronger-than-expected earnings and revenues for its fiscal Q4, but it declined to issue any forward-looking guidance. Apple insisted its iPhone sales numbers were strong on its post-earnings conference call, but the decision not to issue guidance speaks volumes. It wasn't a terrible quarter for Apple, but these Big Tech darlings need to hit home runs every quarter to sustain their elevated valuations. Apple could have some trouble gaining ground in the weeks ahead as a result of the sentiment shift. |
Expedia Group [EXPE] - Last Close: $94.84 Expedia is taking off after a strong earnings report. The travel company reported strong Q3 results and announced a $5 billion share buyback after Thursday's closing bell. Expedia generated EPS of $5.41 against the Street's $4.93 consensus. Revenues of $3.929 also surpassed analysts' $3.857 billion estimate. The company said quarterly booked rooms were up 9% compared to last year, and reiterated its guidance for double-digit topline growth. EXPE is leading the S&P 500 with a 10.4% gain. My Take: Travel is back! EXPE topped out at $120 per share a few months ago. Could this be the beginning of a pivot? DigitalOcean [DOCN] - Last Close: $21.23 DigitalOcean is rallying after an earnings report. The cloud computing company reported its fiscal Q4 results after Thursday's close, and investors are cheering the results. DigitalOcean reported EPS of $0.44 against the Street's $0.38 target, and its $177.06 million revenue figure beat their $173.32 million target as well. The company also released Q4 guidance that surpassed expectations, and shares are taking off as a result. DOCN is one of this morning's top stocks with a 23.2% gain. My Take: DOCN has suffered a long draw down since it hit a 52-week high of $51 in July. However, it could be on the comeback trail. Volume is spiking, and its 11.91% short percentage means a short squeeze could be in the cards. Turnstone Biologics [TSBX] - Last Close: $3.29 A clinical update is lifting shares of Turnstone Bio today. The tiny biotech said it will present preclinical data from a study of its Tumor-Infiltrating Lymphocyte (TIL) therapy at an upcoming industry conference. Turnstone said it will present four clinical posters at on Nov. 4th starting at 9 a.m. at the Society for Immunotherapy of Cancer (SITC) in San Diego. CSO Stewart Abbot said, "We are pleased to share the promising results presented at SITC that further highlight our differentiated approach." TSBX is today's top premarket stock with a 41.3% gain. My Take: TSBX is getting a boost from this press release, but we won't get the full picture until it presents the clinical data. Be careful with this one. Werewolf Therapeutics [HOWL] - Last Close: $2.15 New clinical data is boosting Werewolf Therapeutics today. The tiny biotech presented preliminary data from a Phase 1/1b trial establishing proof of mechanism for WTX-124 at an industry conference. Werewolf said early data on WTX-124 provides "compelling early evidence of dose-dependent biomarker and antitumor activity." in certain cancers. The drug was well tolerated, and the company plans to launch a continued dose-escalation cohort sometime in this first half of 2024. HOWL is one of today's top movers with a 41.4% premarket gain. My Take: HOWL has been very volatile lately, but it has an intact up-trend. This catalyst could help it break through into a new trading range. Gainers - Altamira Therapeutics [CYTO] >> +23.4%
- Qurate Retail [QRTEA] >> +22.7%
- Bioamerica [BMRA] >> +14.5%
Decliners - Bill Com [BILL] >> (30.8%)
- Nextimmune [NEXI] >> (17.1%)
- Fortinet [FTNT] >> (19.8%)
DBA Sempra [SRE] ... AM
Dominion Energy [D] ... AM
Gartner [IT] ... AM
Cardinal Health [CAH] ... AM
Church & Dwight Company [CHD] ... AM
Cboe Global Markets [CBOE] ... AM
Corebridge Financial [CRBG] ... AM
Microchip Technology Incorporated [MCHP] ... PM
- Jobs Report [Oct] ... 8:30a
- S&P U.S. services PMI [Oct] ... 9:45a
- ISM services [Oct] ... 10:00a
|
Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Stock Dork" Taylor Disclaimer © 2023 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
